Categories AlphaGraphs, Earnings, LATEST, Other Industries

Abbott posts strong Q3 results, narrows full year outlook

Pharmaceutical giant Abbott Laboratories (ABT) delivered a 12% increase in third-quarter revenue to $7.7 billion, helped by a 43% increase in diagnostics product sales. The top line surpassed market consensus, which was projected at $7.67 billion.

However, net income from continuing operations fell to $563 million or 31 cents per share, compared to $603 million, or 32 cents per share a year ago. On an adjusted basis, Abbott reported better-than-expected earnings of 75 cents per share, a cent higher than the street expectation.

Abbott Q3 earnings
image courtesy: Open Grid Scheduler

“We achieved another quarter of strong growth and our new product pipeline continues to be highly productive. In spite of increasing currency headwinds, we’re well-positioned to achieve the upper end of our initial full-year guidance,” CEO Miles D. White said in a statement.

The Illinois-based company, meanwhile, narrowed its full-year earnings outlook range on a GAAP basis to $1.33 to $1.35 per share, primarily due to headwinds in the international markets posed by a stronger US dollar.  Excluding one-off items, Abbott expects to earn $2.87 to $2.89 per share.

During the third quarter, sale of Diagnostics products saw the biggest jump of 42.6% to 1.8% billion. The biggest segment, Medical Devices, witnessed a modest 8% growth while the sale of Nutrition products grew 4% during the third quarter.

Abbott posts 17% sales growth for Q2; beats estimates

Abbott shares were down about 2% during pre-market trading on Wednesday.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips. 

Also Read:  Earnings Preview: Q2 results may set the tone for Avid Bioservices’ recovery

Most Popular

Levi Strauss (LEVI): Digital maintains momentum amid pandemic-induced store closures

Amid the COVID-19 pandemic, several retailers were forced to close their stores but in turn witnessed a pickup in their digital business. Levi Strauss & Co. (NYSE: LEVI) is the

Mattel’s (MAT) transformation plan will depend on how pandemic plays out

The ongoing market turmoil has upset the growth strategy set by Mattel, Inc. (NASDAQ: MAT), with focus on transitioning into an IP-driven company. Currently, the maker of legendary brands like

Lemonade (LMND): A successful IPO of 2020

The usage of artificial intelligence (AI) has accelerated rapidly in the fintech industry. Many insurance companies are using AI to compete with their competitors. These insurance companies use AI in

2 thoughts on “Abbott posts strong Q3 results, narrows full year outlook

Comments are closed.

Top